Avidity Biosciences (RNA) announced that the U.S. FDA has granted Breakthrough Therapy designation to delpacibart zotadirsen for the treatment of Duchenne muscular dystrophy in people living with mutations amenable to exon 44 skipping.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity, Phathom mentioned as potential takeout targets at Needham
- Avidity Biosciences Positioned for Leadership in Muscular Dystrophy with Strategic Regulatory Advancements
- Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks
- Avidity Biosciences price target raised to $70 from $60 at Evercore ISI
- Avidity Biosciences: Promising Advancements and Strategic Positioning Drive Buy Rating